DK1373502T3 - Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf - Google Patents

Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf

Info

Publication number
DK1373502T3
DK1373502T3 DK02706572.1T DK02706572T DK1373502T3 DK 1373502 T3 DK1373502 T3 DK 1373502T3 DK 02706572 T DK02706572 T DK 02706572T DK 1373502 T3 DK1373502 T3 DK 1373502T3
Authority
DK
Denmark
Prior art keywords
methods
manf
neuronal survival
dopaminergic neuronal
causes
Prior art date
Application number
DK02706572.1T
Other languages
English (en)
Inventor
John W Commissiong
Andrei A Raibekas
Original Assignee
Amarantus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23061211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1373502(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarantus Therapeutics Inc filed Critical Amarantus Therapeutics Inc
Application granted granted Critical
Publication of DK1373502T3 publication Critical patent/DK1373502T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK02706572.1T 2001-03-20 2002-03-20 Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf DK1373502T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27751601P 2001-03-20 2001-03-20
PCT/CA2002/000373 WO2002074956A2 (en) 2001-03-20 2002-03-20 Dopaminergic neuronal survival-promoting factors and uses thereof

Publications (1)

Publication Number Publication Date
DK1373502T3 true DK1373502T3 (da) 2011-01-10

Family

ID=23061211

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02706572.1T DK1373502T3 (da) 2001-03-20 2002-03-20 Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf

Country Status (9)

Country Link
US (5) US20020182198A1 (da)
EP (1) EP1373502B8 (da)
JP (1) JP2004528835A (da)
AT (1) ATE485377T1 (da)
CA (1) CA2441740A1 (da)
DE (1) DE60238038D1 (da)
DK (1) DK1373502T3 (da)
ES (1) ES2353490T3 (da)
WO (1) WO2002074956A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074956A2 (en) 2001-03-20 2002-09-26 Prescient Neuropharma Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
WO2005005471A2 (en) 2003-07-11 2005-01-20 Develogen Aktiengesellschaft Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
ATE480559T1 (de) * 2005-12-14 2010-09-15 Licentia Ltd Verwendungen eines neurotrophischen faktors
CN102083456B (zh) * 2008-03-25 2015-12-02 阿姆拉特斯治疗公司 神经退行性障碍
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
WO2011038366A1 (en) * 2009-09-25 2011-03-31 Amarantus Therapeutics, Inc. Dopaminergic selective factors
ES2594605T3 (es) * 2011-06-09 2016-12-21 University Of Miami Factores neurotróficos MANF y CDNF para uso en el tratamiento de trastornos de la retina
FI20115870A0 (fi) * 2011-09-05 2011-09-05 Urmas Arumaee Neuroprotektiiviset soluihin tunkeutuvat peptidit
JP2015508155A (ja) 2012-01-24 2015-03-16 ユニバーシティ オブ マサチューセッツ 膵臓β細胞障害における可溶性ＭＡＮＦ
WO2015149005A1 (en) * 2014-03-28 2015-10-01 Buck Institute For Research On Aging Methods and compositions for modulating the immune system
EP3377089B1 (en) * 2015-11-18 2020-04-08 Herantis Pharma Plc Compositions comprising cdnf for use in the intranasal treatment of central nervous system diseases
SG11202009341TA (en) * 2018-03-29 2020-10-29 Helsingin Yliopisto C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof
CN113292656B (zh) * 2020-02-21 2022-10-25 四川大学华西医院 用于防治肥胖的中脑星形胶质细胞源性神经营养因子的融合蛋白

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383076A1 (en) * 1999-09-16 2001-03-22 Neurotrophic Bioscience, Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
AU7452300A (en) * 1999-10-01 2001-05-10 Kyowa Hakko Kogyo Co. Ltd. Shear stress-response dna
WO2001070174A2 (en) * 2000-03-21 2001-09-27 Curagen Corporation Vegf-modulated genes and methods employing them
WO2002074956A2 (en) 2001-03-20 2002-09-26 Prescient Neuropharma Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
CA2441327A1 (en) * 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
CA2458207A1 (en) * 2001-05-03 2002-11-14 Murdoch Childrens Research Institute Determination of a genetic predisposition for behavioural disorders
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
US20060195915A1 (en) 2002-08-30 2006-08-31 Licentia Ltd. Novel neurotrophic factor protein and uses thereof
CN102083456B (zh) 2008-03-25 2015-12-02 阿姆拉特斯治疗公司 神经退行性障碍
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
ES2594605T3 (es) 2011-06-09 2016-12-21 University Of Miami Factores neurotróficos MANF y CDNF para uso en el tratamiento de trastornos de la retina

Also Published As

Publication number Publication date
JP2004528835A (ja) 2004-09-24
EP1373502A2 (en) 2004-01-02
DE60238038D1 (de) 2010-12-02
ATE485377T1 (de) 2010-11-15
EP1373502B1 (en) 2010-10-20
US20020182198A1 (en) 2002-12-05
WO2002074956A2 (en) 2002-09-26
ES2353490T3 (es) 2011-03-02
US8084425B2 (en) 2011-12-27
US20100119491A1 (en) 2010-05-13
US20160152673A1 (en) 2016-06-02
US20170298110A1 (en) 2017-10-19
WO2002074956A3 (en) 2003-07-10
EP1373502B8 (en) 2010-12-22
US9115208B2 (en) 2015-08-25
CA2441740A1 (en) 2002-09-26
US20130078220A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
DK1373502T3 (da) Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
BRPI0015533B8 (pt) enzima alfa-l-iduronidase humana recombinante, composição farmacêutica compreendendo a mesma e método para sua purificação
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
DE60335244D1 (de) Behandlung von verletzungen des zentralen nervensystems
ATE229806T1 (de) Wirkstoff zur behandlung neurodegenerativer störungen
GR20010300006T1 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
EA200401365A1 (ru) Способы лечения илеуса
NO20092741L (no) DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser
ATE300052T1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
DK1186672T3 (da) Polymorfismer i det humane gen for organiskaniontransporter C (OATP-C)
WO2001019851A3 (en) Opaminergic neuronal survival-promoting factors and uses thereof
DE69934415D1 (de) Neuartiges collectin
PT1255734E (pt) Derivados de isatina com actividade neurotrofica
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
BR0314541A (pt) Tratamento de demência e doença de parkinson
ATE391915T1 (de) Verwendung des proteins grf-1 zur auswahl von molekülen
DE60004093D1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
DE60224778D1 (de) Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen
AU6039400A (en) Mutated nurr1 gene